Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

被引：0

作者：

Moussa, Mohamad ^{[1
]}

Papatsoris, Athanasios ^{[2
]}

Abou Chakra, Mohamed ^{[1
]}

Dellis, Athanasios ^{[2
,3
]}

机构：

[1] Lebanese Univ, Univ Med Ctr, Al Zahraa Hosp, Dept Urol, Beirut, Lebanon

[2] Natl & Kapodistrian Univ Athens, Sismanoglio Hosp, Sch Med, Dept Urol 2, Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Sch Med, Dept Surg, Athens, Greece

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

enfortumab vedotin; bladder cancer; metastasis; urothelial cancer; BLADDER-CANCER; PHASE-III; CHEMOTHERAPY; TRIAL; AGENT;

D O I：

10.2147/DDDT.S240654

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.

引用

页码：453 / 462

页数：10

共 29 条

[1] 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest [J].

Al Shaer, Danah ;

Al Musaimi, Othman ;

Albericio, Fernando ;

de la Torre, Beatriz G. .

PHARMACEUTICALS, 2020, 13 (03)

[2]

[Anonymous], 2019, PADCEV APPROVAL LETT

[3]

Boni Valentina, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI 10.1200/EDBK_281107

[4]

Cancer Stat Facts: Bladder Cancer, 2019, NIH NCI SURV EP END

[5] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models [J].

Challita-Eid, Pia M. ;

Satpayev, Daulet ;

Yang, Peng ;

An, Zili ;

Morrison, Karen ;

Shostak, Yuriy ;

Raitano, Arthur ;

Nadell, Rossana ;

Liu, Wendy ;

Lortie, Dawn Ratay ;

Capo, Linnette ;

Verlinsky, Alla ;

Leavitt, Monica ;

Malik, Faisal ;

Avina, Hector ;

Guevara, Claudia I. ;

Dinh, Nick ;

Karki, Sher ;

Anand, Banmeet S. ;

Pereira, Daniel S. ;

Joseph, Ingrid B. J. ;

Donate, Fernando ;

Morrison, Kendall ;

Stover, David R. .

CANCER RESEARCH, 2016, 76 (10) :3003-3013

[6]

FDA, 2021, RES INF APPR DRUGS

[7] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J].

Ferlay, J. ;

Colombet, M. ;

Soerjomataram, I. ;

Mathers, C. ;

Parkin, D. M. ;

Pineros, M. ;

Znaor, A. ;

Bray, F. .

INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) :1941-1953

[8] Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook [J].

Gopalakrishnan, Dharmesh ;

Koshkin, Vadim S. ;

Ornstein, Moshe C. ;

Papatsoris, Athanasios ;

Grivas, Petros .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 :1019-1040

[9]

Grivas Petros, 2019, Am Soc Clin Oncol Educ Book, V39, P284, DOI 10.1200/EDBK_237449

[10] Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma [J].

Halford, Zachery ;

Anderson, Mary Kate ;

Clark, Matthew D. .

ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) :772-782

← 1 2 3 →